Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review
Frontiers in Nutrition · 17.06.2026 · 13
DOI: 10.3389/fnut.2026.1859472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 17.06.2026. Verfasst von Jennie Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Helfgott Research Institute, National University of Natural Medicine, Portland, OR, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCCIH NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Growing translational evidence indicates that the physiologically relevant effects of dietary (poly)phenols are largely mediated by gut microbial metabolism, resulting in bioactive microbial-derived (poly)phenol metabolites (MPMs). However, clinical evidence linking specific MPMs to defined health outcomes has not been comprehensively synthesized.
Objective
This scoping review characterizes clinical studies assessing associations between MPMs and human health and disease.
Methods
We systematically searched MEDLINE (PubMed), Embase (Elsevier), Web of Science (SCIE, ESCI), Scopus, ProQuest Health and Medical, the Cochrane Library, and ClinicalTrials.gov . Eligible studies quantified specific MPMs (e.g., urolithins, phenolic acids) in human biological specimens and assessed associations with biological or clinical outcomes. Two reviewers independently screened and extracted data using standardized forms. Findings were synthesized qualitatively.
Results
Seventy studies across cardiometabolic, inflammatory/oxidative stress, neurological, gastrointestinal, cancer, musculoskeletal, epigenetic, and respiratory domains were included. Evidence was most concentrated in cardiometabolic outcomes ( n = 38), with recurrent associations involving urolithins and phenolic acid derivatives. This was followed by inflammatory/oxidative stress ( n = 15) and neurological outcomes ( n = 11). Musculoskeletal, epigenetic, and respiratory outcomes were least represented. Substantial heterogeneity in study design, metabolite measurement, and outcome reporting limited cross-study comparability.
Conclusion
Specific MPMs may contribute to inter-individual variability in diet-related health responses. Standardized metabolite assessment and prospective trials evaluating direct supplementation of specific microbial metabolites, particularly in individuals with limited systemic exposure, are needed to clarify their role in human health and inform precision nutrition strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Helfgott Research Institute, National University of Natural Medicine, Portland, OR, United States.
- Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO, United States.
- Department of Cell and Molecular Biology, Colorado State University, Fort Collins, CO, United States.
Förderung
- NIDDK NIH HHS
- NCCIH NIH HHS
- National Institutes of Health
- Colorado State University
Zitieren
APA
Brown, J., Norby-Adams, L., Ghanem, N., Lewis, A., Goldenberg, J. Z., Weir, T., & Vita, A. A. (2026). Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1859472
Vancouver
Brown J, Norby-Adams L, Ghanem N, Lewis A, Goldenberg JZ, Weir T, et al. Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1859472
BibTeX
@article{Brown2026,
author = {Brown, Jennie and Norby-Adams, Lydia and Ghanem, Nancy and Lewis, Ayda and Goldenberg, Joshua Z and Weir, Tiffany and Vita, Alexandra Adorno},
title = {Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1859472}
}
EUVIMED